2009-11-09 14:25:02 -

BAGSVAERD, DENMARK -- (Marketwire) -- 11/09/09 -- On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.



On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.



Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.



Since the announcement as of 2 November 2009, the following transactions have been made under the programme:

                        Number of shares    Average      Transaction
                                         purchase price  value, DKK
Accumulated, last
announcement                   4,669,099                1,490,518,113
2 November 2009                   75,000       315.9100    23,693,250
3 November 2009                   75,000       316.9650    23,772,375
4 November 2009                   75,000       323.8510    24,288,825
5 November 2009                   80,000       324.2290    25,938,320
6 November 2009                  115,000       320.5820    36,866,930
Accumulated under the
programme                      5,089,099                1,625,077,813

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 57,850 B shares in the period from 2 November 2009 to 6 November 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.



With the transactions stated above, Novo Nordisk owns a total of 29,838,977 treasury shares, corresponding to 4.8% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.



Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                 Investors:

Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
 ekh@novonordisk.com : mailto:ekh@novonordisk.com      mlau@novonordisk.com : mailto:mlau@novonordisk.com 

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                        krop@novonordisk.com : mailto:krop@novonordisk.com 

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
 secl@novonordisk.com : mailto:secl@novonordisk.com     hrmm@novonordisk.com : mailto:hrmm@novonordisk.com 

Company Announcement no 67 / 2009


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.